ALAINA CONTESTABILE: Open Payments
NPI 1083196026 · PELHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,238 in 193 payments from 14 companies in 2025. Trend: 2023 $2,821 · 2024 $2,317 · 2025 $4,238
Food & beverage: $4,238
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 30 | $880 |
| Neurocrine BioSciences, Inc. | 28 | $636 |
| Otsuka America Pharmaceutical, Inc. | 21 | $435 |
| Alkermes, Inc. | 16 | $412 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $410 |
| Lundbeck LLC | 14 | $306 |
| Teva Pharmaceuticals USA, Inc. | 14 | $257 |
| Janssen Pharmaceuticals, Inc | 8 | $193 |
| ABBVIE INC. | 17 | $179 |
| Axsome Therapeutics, Inc. | 8 | $170 |
Products named: FANAPT, INGREZZA, REXULTI, ARISTADA, CAPLYTA, ABILIFY MAINTENA, INVEGA SUSTENNA, VRAYLAR.
Industry payments across AL — which companies pay providers there.
